| Similar Articles |
|---|
 |
The Motley Fool
February 8, 2005
Charly Travers |
Investing in a Cure Drugs in the pipeline offer potential breakthroughs for Alzheimer's disease. Instead of investing in small biotechs that have a lot riding on a single Alzheimer's program, the best way to invest in the field is through a diversified company   |
The Motley Fool
February 7, 2005
Stephen D. Simpson |
Axonyx Gets Crushed The biotech company is hammered by disappointing phase 3 results of an Alzheimer's drug. |
The Motley Fool
February 3, 2004
David Nierengarten |
Big Break for a Small Biotech? Axonyx's new drug for Alzheimer's disease could be first in its class. |
The Motley Fool
October 26, 2004
Charly Travers |
Biotech's 5-Baggers: Part 2 Several hot drugs are generating smoking returns. If the goal for an investor is to aim for one of these five-baggers, then one option is to invest before the company passes through the inflection point. |
The Motley Fool
January 29, 2010
Brian Orelli |
How to Make Billions of Dollars Without Really Trying Lackluster Alzheimer's drugs have been doing it for years. |
The Motley Fool
August 13, 2007
Rich Duprey |
U.K. High Court Forgets to Be NICE A court challenge to place limits on treatment for Alzheimer's disease is upheld. Eisai has said it will appeal the High Court's ruling. It's a bit of a high-stakes gamble. The United Kingdom accounts for just a small portion of Eisai's profits from Aricept. |
The Motley Fool
January 26, 2005
Stephen D. Simpson |
The Pipeline to Biotech Success Looking at drug R&D is the best way to begin assessing biotech companies as possible investment opportunities. |
The Motley Fool
September 1, 2004
W.D. Crotty |
A Pall Falls Over Forest One of Forest Labs' Alzheimer's drugs fails in phase 3 trials. For investors willing to take the political risk, today's drug news has taken a battered stock, with a great balance sheet, to very reasonable price levels. |
The Motley Fool
October 13, 2006
Rich Duprey |
NICE Is Just Dumb The British health agency prohibits the use of certain Alzheimer's treatments because of cost. |
The Motley Fool
September 5, 2008
Brian Lawler |
Why Pfizer Made an Interesting Blockbuster Bet The pharma giant inked a deal worth potentially more than $725 million with development stage drugmaker Medivation to market Medivation's Alzheimer's disease drug Dimebon. |
The Motley Fool
June 29, 2007
Rich Duprey |
No More Mr. NICE Guy Pharmaceuticals take British advisory agency to court to approve Alzheimer's treatment. |
The Motley Fool
May 30, 2006
Rich Duprey |
NICE Not Playing Nice With Alzheimer's The British health authority proposes limiting availability of Alzheimer's treatments because of cost. What will this mean to drug-makers and their shareholders? |
The Motley Fool
January 12, 2005
Charly Travers |
Alzheimer's Drug on the Horizon? Myriad Genetics' innovative technology creates an investment opportunity. |
Chemistry World
August 9, 2012 |
Bapineuzunab dropped Pfizer and Johnson and Johnson have announced that they are ending development of the intravenous Alzheimer's drug bapineuzumab after it failed in two clinical trials. |
The Motley Fool
May 16, 2007
Mike Havrilla |
Waiting on Memory Pharmaceuticals The small-cap biotech is testing a treatment for Alzheimer's, but investors should stand by. |
The Motley Fool
July 14, 2005
Stephen D. Simpson |
Dueling Fools: Protein Design Labs Bear Protein Design Labs could be a big winner, or a major loser. The biotech has a strong business, but today's stock price isn't "great." |
The Motley Fool
October 18, 2006
Rich Duprey |
FDA Expands Alzheimer's Treatment Japan's fourth-largest pharmaceutical Eisai's Aricept wins the right to treat all stages of Alzheimer's. Investors, take note. |
The Motley Fool
February 15, 2005
Charly Travers |
Searching for Cheap Biotechs Can a stock screen turn up a winner? Remember, the screen just gives a short list of potential ideas and some guidance as to where a good place to look may be. But it is not a replacement for doing research on a company's drug programs and management team. |
BusinessWeek
January 8, 2007
Catherine Arnst |
Decoding Alzheimer's After a century, promising treatments at last - and whispers of a cure. |
Pharmaceutical Executive
December 1, 2010
Walter Armstrong |
Alzheimer's: A Disease at a Crossroads The need for new drugs intensifies as more and more Baby Boomers live into advanced old age. The global market is estimated to be worth $20 billion by the end of the decade. |
The Motley Fool
August 28, 2006
Brian Lawler |
The Commandments of Biotech Investing Since long-term successful biotech investing requires accurate risk assessment, you must be aware of the risk you're taking on. Just as with any prospective investment, if you diversify your biotech holdings, you can somewhat mitigate these various risks. |
BusinessWeek
March 27, 2006
Gene G. Marcial |
Cortex Draws A Bead On Hyperactivity When Cortex Pharmaceuticals disclosed on Mar. 8 that its lead drug, CX717, showed favorable results in Phase 2 trials for the treatment of adult ADHD, the stock jumped. |
The Motley Fool
February 10, 2005
Karl Thiel |
The Worst Has Happened. Time to Sell? Biotech stocks can be volatile, but dumping them in response to bad news isn't always the smartest option: Axonyx... Icos Pharmaceuticals... etc. |
Chemistry World
October 8, 2010
Sarah Houlton |
U-turn on Alzheimer's drugs in the UK The UK National Institute for Health and Clinical Excellence proposes that those with mild disease will be able to receive them from early next year, on the basis of growing clinical evidence of their effectiveness. |
The Motley Fool
November 9, 2009
Dave Mock |
A Big Upgrade for Rodman & Renshaw All Motley Fool analysts following investment bank Rodman & Renshaw are bullish, lifting the stock to a five-star rating. |
Chemistry World
November 2, 2006
Michael Gross |
Alzheimer's Century Researchers worldwide are commemorating the centenary of Alois Alzheimer's first description of the dementia named after him. |
BusinessWeek
September 4, 2006
Gene G. Marcial |
A Super Outlook For SuperGen Biotechs have not fared well in this fickle market. |
AskMen.com
Jacob Franek |
Alzheimer's Disease 101 It's only in the last decade or so that we have truly come to understand the various disorders of the brain that are associated with age and, in most cases, Alzheimer's disease is the prime suspect. Read on for some basic information. |
Chemistry World
January 3, 2007
Victoria Gill |
Alzheimer's Protein Fingerprint Alzheimer's disease, a debilitating neurodegenerative disorder that eventually results in wasting of the whole brain, offers a chemical clue that should make it easier to spot and possibly easier to treat. |
